866-997-4948(US-Canada Toll Free)

Impetigo - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 41 Pages

Impetigo - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Impetigo - Pipeline Review, H2 2017, provides an overview of the Impetigo (Infectious Disease) pipeline landscape.

Impetigo is a highly contagious skin condition. Impetigo is caused by two bacteria streptococcus pyogenes and staphylococcus aureus. Symptoms include fluid-filled blisters, itchy rash, skin lesions and swollen lymph nodes. Risk factors include skin-to-skin contact, injury to the skin, having diabetes and having a compromised immune system. Treatment includes antibiotics.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Impetigo - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Impetigo (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Impetigo (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Impetigo and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Impetigo (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Impetigo (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Impetigo (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Impetigo (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Impetigo (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Impetigo (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Impetigo (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Impetigo (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Impetigo - Overview 6
Impetigo - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 11
Impetigo - Therapeutics Assessment 12
Assessment by Target 12
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Impetigo - Companies Involved in Therapeutics Development 20
Destiny Pharma Ltd 20
Foamix Pharmaceuticals Ltd 20
Fujifilm Holdings Corporation 20
Laboratories Ojer Pharma SL 21
Lytix Biopharma AS 21
Impetigo - Drug Profiles 23
FMX-102 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
LTX-109 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
mupirocin - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
ozenoxacin - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Synthetic Peptides for Infectious Disease - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
XF-70 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Impetigo - Dormant Projects 32
Impetigo - Discontinued Products 33
Impetigo - Product Development Milestones 34
Featured News & Press Releases 34
May 08, 2017: Cipher Pharmaceuticals Receives Health Canada Approval of OZANEX (ozenoxacin cream 1%) 34
Jul 12, 2016: Cipher Pharmaceuticals announces Ozenoxacin accepted for review by Health Canada 34
Jun 27, 2016: Medimetriks Pharmaceuticals New Drug Application for Ozenoxacin Cream, 1% Accepted for Review by FDA 35
Jun 27, 2016: Medimetriks Pharmaceuticals Submits a New Drug Application to FDA for Ozenoxacin Cream, 1%, a Novel Impetigo Treatment 35
Jun 12, 2014: Medimetriks Pharmaceuticals Announces that the Second Phase III Study for Ozenoxacin has been Initiated by Ferrer 36
Jun 05, 2013: Ferrer Completes Phase III Clinical Trial Of Ozenoxacin In Adult And Pediatric Patients With Impetigo 36
Feb 22, 2013: Lytix Biopharma Enrolls First Patient In LTX-109 Phase II Proof Of Concept Infection Study 37
Oct 05, 2012: Ferrer Successfully Completes Absorption, Tolerability And Safety Study In Juveniles As Young As Two Months Of Age For New Antibacterial Compound Ozenoxacin 38
Jan 19, 2012: Ferrer Initiates Phase III Clinical Studies For Ozenoxacin In Development As Topical Treatment For Impetigo And Other Infectious Dermatological Conditions 38
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 40
Disclaimer 41

List of Tables
Number of Products under Development for Impetigo, H2 2017 7
Number of Products under Development by Companies, H2 2017 8
Number of Products under Development by Universities/Institutes, H2 2017 9
Products under Development by Companies, H2 2017 10
Products under Development by Universities/Institutes, H2 2017 11
Number of Products by Stage and Target, H2 2017 13
Number of Products by Stage and Mechanism of Action, H2 2017 15
Number of Products by Stage and Route of Administration, H2 2017 17
Number of Products by Stage and Molecule Type, H2 2017 19
Impetigo - Pipeline by Destiny Pharma Ltd, H2 2017 20
Impetigo - Pipeline by Foamix Pharmaceuticals Ltd, H2 2017 20
Impetigo - Pipeline by Fujifilm Holdings Corporation, H2 2017 21
Impetigo - Pipeline by Laboratories Ojer Pharma SL, H2 2017 21
Impetigo - Pipeline by Lytix Biopharma AS, H2 2017 22
Impetigo - Dormant Projects, H2 2017 32
Impetigo - Discontinued Products, H2 2017 33

List of Figures
Number of Products under Development for Impetigo, H2 2017 7
Number of Products under Development by Companies, H2 2017 8
Number of Products by Targets, H2 2017 12
Number of Products by Stage and Targets, H2 2017 12
Number of Products by Mechanism of Actions, H2 2017 14
Number of Products by Stage and Mechanism of Actions, H2 2017 14
Number of Products by Routes of Administration, H2 2017 16
Number of Products by Stage and Routes of Administration, H2 2017 16
Number of Products by Molecule Types, H2 2017 18
Number of Products by Stage and Molecule Types, H2 2017 18

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *